The role of tissue factor and tissue factor pathway inhibitor in health and disease states

Journal of Veterinary Emergency and Critical Care

Volumn 19, Issue 1, 2009, Pages 23-29

  DelGiudice, Louis A ^a,c   White, George A ^b  

^a Animal Emergency and Referral Hospital   (United States)

^b VCA Alpine Animal Hospital   (Australia)

^c NONE   (United States)

Author keywords

Angiogenesis; Coagulation; Inflammation; Sepsis

Indexed keywords

ANIMALIA;

LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; DRUG ANTAGONISM; HUMAN; METABOLISM; PHYSIOLOGY;

ANIMALS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; HUMANS; LIPOPROTEINS; THROMBOPLASTIN;

EID: 61449195189     PISSN: 14793261     EISSN: 14764431     Source Type: Journal    
DOI: 10.1111/j.1476-4431.2008.00380.x     Document Type: Article

References (76)

1. Spek C. Tissue factor: from 'just one the coagulation factors' to a major player in physiology. Blood Coagul Fibrinolysis 2004 15 (1, suppl) : S3 S10.
2. Price GC, Thompson SA, Kam PCA. Tissue factor and tissue factor pathway inhibitor. Anaesthesia 2004 59 : 483 492.
3. Hopper K, Bateman S. An updated view of hemostasis: mechanisms of hemostatic dysfunction associated with sepsis. J Vet Emerg Crit Care 2005 15 (2) : 83 91.
4. Broze GJ. The rediscovery and isolation of TFPI. J Thromb Haemost 2003 1 (8) : 1671 1675.
5. Roncales FJ, Sancho JM. Coagulation activators, In : Feldman BF, Zinkl JG, Jain NC. eds. Schalm's Veterinary Hematology, 5th ed. Ames : Blackwell Publishing 2006, pp. 532 537.
6. Doshi SN, Marmur JD. Evolving role of tissue factor and its pathway inhibitor. Crit Care Med 2002 30 (5, suppl) : S241 S250.
7. Peppelenbosch MP, Versteeg HH. Cell biology of tissue factor, and unusual member of the cytokine receptor family. Trends Cardiovasc Med 2001 11 (8) : 335 339.
8. Duffy TC, Kirby R, Rudloff E. Critical role of the vascular endothelial cell in health and disease: a review article. J Vet Emerg Crit Care 2004 14 (2) : 84 99.
9. Osterud B, Bajaj MS, Bajaj SP. Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiological and pathologic conditions. J Thromb Haemost 1995 73 (5) : 873 875.
10. Eilertsen KE, Osterud B. Tissue factor: (patho)physiology and cellular biology. Blood Coagul Fibrinolysis 2004 15 (7) : 521 538.
11. Golino P, Ragni M, Cimmino G, et al. Role of tissue factor pathway inhibitor in the regulation of tissue factor-dependent blood coagulation. Cardiovasc Drug Rev 2002 20 (1) : 67 80.
12. Panteleev MA, Zaritsina VI, Ataullakhanov FI. Tissue factor pathway inhibitor. Eur J Biochem 2002 269 : 2016 2031.
13. Narita M, Bu G, Olinss GM, et al. Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vivo. J Biol Chem 1995 270 (42) : 24800 24804.
14. Johnstone IB. Coagulation inhibitors, In : Feldman BF, Zinkl JG, Jain NC. eds. Schal's Veterinary Hematology, 5th ed. Ames : Blackwell Publishing 2006, pp. 538 543.
15. Aird WC. Coagulation. Crit Care Med 2005 33 (12, suppl) : S485 S487.
16. Monroe DM, Key NS. The tissue factor-factor VIIa complex: procoagulant activity, regulation, and multitasking. J Thromb Haemost 2007 5 : 1097 1105.
17. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 1999 340 (20) : 1555 1564.
18. Mann KG. Thrombin formation. Chest 2003 124 (3, suppl) : S4 S10.
19. Good LI, Manning AM. Thromboembolic disease: physicology of hemostasis and pathophysiology of thrombosis. Compend Contin Educ Vet 2003 25 (9) : 650 659.
20. Osterud B. Tissue factor expression by monocytes: regulation and pathophysiological roles. Blood Coagul Fibrinolysis 1998 9 (1, suppl) : S9 S14.
21. Monroe DM, Roberts HR, Hoffman M. Platelet procoagulant complex assembly in a tissue-factor initiated system. Br J Haematol 1994 88 : 364 371.
22. Levi M. Platelets. Crit Care Med 2005 33 (12, suppl) : S523 S525.
23. Polgar J, Matuskova J, Wagner DD. The P-selectin, tissue factor, coagulation triad. J Thromb Haemost 2005 3 (8) : 1590 1596.
24. Dahm AEA, Anderson TO, Rosendaal F, et al. A novel anti-coagulant assay of tissue factor pathway inhibitor I (TFPI). J Thromb Haemost 2004 3 : 651 658.
25. Golino P. The inhibitors of the tissue factor: factor VII pathway. Thromb Res 2002 106 : 257 265.
26. Li Y, Rodriquez M, Spencer FA, et al. Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor inhibitor release: a model of assessing intrinsic thromboresistance. J Thromb Thrombolysis 2002 14 (2) : 123 129.
27. deLaforcade AM, Freeman LM, Shaw SP, et al. Hemostatic changes in dogs with naturally occurring sepsis. J Vet Intern Med 2003 17 : 674 679.
28. Weiss DJ, Rashid J. The sepsis-coagulant axis: a review. J Vet Intern Med 1998 12 : 317 324.
29. Hack CE. Tissue factor pathway of coagulation in sepsis. Crit Care Med 2000 28 (suppl 9) : S25 S30.
30. Hack CE, Zeerleder S. The endothelium in sepsis: source of and a target of inflammation. Crit Care Med 2001 29 (7, suppl) : S21 S27.
31. Cate H. Pathophysiology of disseminated intravascular coagulation in sepsis. Crit Care Med 2000 28 (9, suppl) : S9 S11.
32. Levi M, ten Cate H, Bauer KA, et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994 93 : 114 120.
33. Taylor FB, Chang A, Ruf W, et al. Lethal E. coli septic shock in prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991 33 : 127 134.
34. Pawlinski R, Mackman N. Tissue factor, coagulation proteases, and protease-activated receptors in endotoxemia and sepsis. Crit Care Med 2004 32 (5, suppl) : S293 S297.
35. Creasey AA, Reinhart K. Tissue factor pathway inhibitor activity in severe sepsis. Crit Care Med 2001 29 (7, suppl) : S126 S129.
36. Gando S, Kameue T, Morimoto Y, et al. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med 2002 30 (8) : 1729 1734.
37. Smithies MN, Weaver CB. Role of the tissue factor pathway in the pathogenesis and management of multiple organ failure. Blood Coagul Fibrinolysis 2004 15 (1, suppl) : S11 S20.
38. Creasey AA, Chang ACK, Feigen L, et al. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993 91 (6) : 2850 2860.
39. Carr C, Bild GS, Chang ACK, et al. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon Gram-negative model of septic shock. Circ Shock 1995 44 (3) : 126 137.
40. Camerota AJ, Creasey ASA, Patla V, et al. Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with Gram-negative peritonitis. J Infect Dis 1998 177 : 668 677.
41. Creasey AA. New potential therapeutic modalities: tissue factor pathway inhibitor. Sepsis 1999 3 : 173 182.
42. Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med 2000 28 (9, suppl) : S31 S33.
43. Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001 29 (11) : 2081 2089.
44. Russell J. Management of sepsis. J Engl J Med 2006 355 : 1699 1713.
45. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis. J Am Med Assoc 2003 290 (2) : 238 247.
46. Donahue SM, Otto CM. Thromboelastography: a tool for measuring hypercoagulability, hypocoagulability and fibrinolysis. J Vet Emerg Crit Care 2005 15 (1) : 9 16.
47. Wiinberg B, Jensen AL, Johansson PI, et al. Thromboelastographic evaluation of hemostatic function in dogs with disseminated intravascular coagulation. J Vet Intern Med 2008 22 : 357 365.
48. Gando S, Nanzaki S, Morimoto Y, et al. Tissue factor pathway inhibitor response does not correlate with tissue factor induced disseminated intravascular coagulation and multiple organ dysfunction syndrome in trauma patients. Crit Care Med 2001 29 (2) : 262 266.
49. Marshall J. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 2001 29 (7, suppl) : S99 S106.
50. Levi M, de Jonge E, van Der Poll T, et al. Novel approaches to the management of disseminated intravascular coagulation. Crit Care Med 2000 28 (9, suppl) : S20 S24.
51. Asakura H, Ontachi Y, Mizutani T, et al. Elevated levels of free tissue factor pathway inhibitor antigen in cases of disseminated intravascular coagulation caused by various underlying diseases. Blood Coagul Fibrinolysis 2001 12 : 1 8.
52. Brohi K, Singh J, Heron M, et al. Acute traumatic coagulopathy. J Trauma 2003 54 : 1127 1130.
53. Utter Gh, Owings JT, Jacoby RB, et al. Injury induces increased monocyte expression of tissue factor: factors associated with head injury attenuate the injury-related monocyte expression of tissue factor. J Trauma 2002 52 : 1071 1077.
54. Gando S, Nanzaki S, Kemmotsu O. Coagulofibrinolytic changes after isolated head injury are not different from those in trauma patients without head injury. J Trauma 1999 46 (6) : 1070 1076.
55. Gando S, Kameue T, Matsuda N, et al. Imbalances between the levels of tissue factor and tissue factor pathway inhibitor in ARDS patients. Thromb Res 2003 109 : 119 124.
56. Gando S, Nanzaki S, Morimoto Y, et al. Systemic activation of tissue-factor dependent coagulation pathway in evolving acute respiratory distress syndrome in patients with trauma and sepsis. J Trauma 1999 47 (4) : 719 723.
57. Luther T, Flossel C, Mackman N, et al. Tissue factor expression during human and mouse development. Am J Path 1996 149 (1) : 101 113.
58. Davis DR, Erlich JH. Cardiac tissue factor: roles in physiology and fibrosis. Clin Exp Pharmacol Physiol 2008 35 : 342 348.
59. Pawlinski R, Fernandes A, Kehrle B, et al. Tissue factor deficiency causes cardiac fibrosis and left ventricular dysfunction. Proc Natl Acad Sci USA 2002 99 (24) : 15333 15338.
60. Morange PE, Blankenberg S, Alessi C, et al. Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the ArtheroGene study. J Thromb Haemost 2006 5 : 475 482.
61. Stellbaum C, Willich T, Boltzen U, et al. Clopidogrel-mediated reduction of circulating tissue factor in patients with stable coronary artery disease. Eur J Haemotol 2007 78 : 347 352.
62. Himber J, Wohlgensinger C, Roux S, et al. Inhibition of tissue factor limits the growth of venous thrombus in the rabbit. J Thromb Haemost 2003 1 : 889 895.
63. Ruf W, Dorfleutner A, Riewald M. Specificity of coagulation factor signaling. J Thromb Haemost 2003 1 : 1495 1503.
64. Ruf W. Protease-activated receptor signaling in the regulation of inflammation. Crit Care Med 2004 32 (5, suppl) : S287 S292.
65. Carmeliet P, Mackman N, Moons L, et al. Role of tissue factor in embryonic blood vessel development. Nature 1996 383 : 73 75.
66. Versteeg HH, Peppelenbosch MP, Spek CA. Tissue factor signal transduction in angiogenesis. Carcinogenesis 2003 24 (6) : 1009 1013.
67. Belting M, Dorrell MI, Sandgren S, et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004 10 (5) : 502 509.
68. Contrino J, Hair G, Kreutzer D, et al. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast cancer. Nat Med 1996 2 (2) : 209 215.
69. Kakkar AK, Chinswangwatanakul V, Lemoine NR, et al. Role of tissue factor expression on tumour cell invasion and growth in experimental adenocarcinoma. Br J Surg 1999 86 : 890 894.
70. Kageshita T, Funasaka Y, Ichihashi M, et al. Tissue factor expression and serum level in patients with melanoma does not correlate and disease progression. Pigment Cell Res 2001 14 : 195 200.
71. Amirkhosravi A, Meyer T, Chang JY, et al. Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost 2002 87 : 930 936.
72. Jiang X, Bailly MA, Pannetti TS, et al. Formation of tissue factor-factor VIIa-factor Xa complex promotes cellular signaling and migration of human breast cancer cells. J Thromb Haemost 2003 2 : 93 101.
73. Lopez-Pedrera C, Barbarroja N, Dorado G, et al. Tissue factor as an effector on angiogenesis and tumor progression in hematological malignancies. Leukemia 2006 20 : 1331 1340.
74. Kageshita T, Funasaka Y, Ichihashi M, et al. Differential expression of tissue factor and tissue factor pathway inhibitor in metastatic melanoma lesions. Pigment Cell Res 2002 15 : 212 216.
75. Rak J, Milsom C, May L, et al. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thrombos Hemost 2006 32 (1) : 54 70.
76. Kristensen AT, Wiinberg B, Jessen LR, et al. Evaluation of human recombinant tissue factor-activated thromboelastography in 49 dogs with neoplasia. J Vet Intern Med 2008 22 : 140 147.